ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

RVTY vs TXG // EV/EBITDA & P/E VALUATION

Revvity Inc. (NYSE) VS. 10x Genomics Inc. (NASDAQ) • 15-METRIC TALLY: RVTY 7 — TXG 5
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RVTY VS. TXG) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC RVTY TXG SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 69.10% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 3.10% -5.70% +8.80 RVTY /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE 48.2x — — TIE /valuation <GO>
Free Cash Flow Yield 2.75% 1.22% +1.53 RVTY /fcf-yield <GO>
Operating Margin 12.50% -9.50% +22.00 RVTY /operating-margins <GO>
Net Profit Margin 8.40% -6.80% +15.20 RVTY /net-margins <GO>
Revenue Growth (YoY) 3.70% 5.20% -1.50 TXG /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.18% 0.00% +0.18 RVTY /dividend-safety <GO>
Altman Z-Score & Debt/Equity 3.37 25.02 -21.65 TXG /balance-sheet <GO>
Piotroski F-Score Quality 7/9 8/9 -1.00 TXG /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 64.5 55.0 +9.50 RVTY /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 0.95 1.15 -0.20 TXG /macro-sensitivity <GO>
Forward P/E Multiple 71.3x 24.0x +47.30 TXG /forward-pe <GO>
Enterprise Scale & Market Cap $18.50B $10.63B $7.87B RVTY /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR RVTY REV TXG REV RVTY GROSS % TXG GROSS % RVTY FCF TXG FCF
FY 2025 $2.86B $642.8M — 69.1% $509.4M $130.1M
FY 2024 $2.76B $610.8M — 67.9% $541.7M -$5.7M
FY 2023 $2.75B $618.7M — — -$32.5M -$43.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RVTY // BETA 0.95
TXG // BETA 1.15